ЛИТЕРАТУРА

Поставить закладку

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89(11):3909-18.
2. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265
3. Buske C, Hoster E, Dreyling M, Hasford J, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated frontline with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504-1508
4. FedericoM,BelleiM,MarcheselliL,etal.Follicularlymphomainternational prognostic index 2: a new prognostic index for follicular lymphoma developedbytheinternationalfollicularlymphomaprognosticfactorproject. JClinOncol.2009;27:4555-4652
5. Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. SeminHematol.1988;25(2Suppl2):11-6
6. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicularlymphomasbetweenaninitialno-treatmentpolicy,prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des LymphomesFolliculaires.Grouped'EtudedesLymphomesdel'Adulte.JClin Oncol.1997;15(3):1110-7
7. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202-8
8. Нестерова Е.С., Кравченко С.К., Гемджян Э.Г., и соавт. Итоги десятилетного опыта лечения больных фолликулярной лимфомой. Гематологияитрансфузиология.2012;57(5):3-8
9. ArdeshnaKM,SmithP,NortonA,etal.Long-termeffectofawatchandwait policyversusimmediatesystemictreatmentforasymptomaticadvanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-22
10. Ardeshna K, Qian W, Smith P, et al. An Intergroup Randomised Trial of RituximabVersusaWatchandWaitStrategyInPatientswithStageII,III, IV,Asymptomatic,Non-BulkyFollicularLymphoma(Grades1,2and3a).A Preliminary Analysis. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract6.
11. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des LymphomesFolliculaires.Grouped'EtudedesLymphomesdel'Adulte.JClin Oncol.1997;15(3):1110-7
12. MacManus PM, Hoppe RT. Is radiotherapy curative for stage I and II low gradefollicularlymphoma?Resultsofalongtermfollow-upstudyofpatients treatedatStanfordUniversity.JClinOncol.1996;14:1282-1290
13. Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797-806
14. Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51(5):1219-27
15. Guadagnolo BA, Li S, Neuberg D, Ng A, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64(3):928-34
16. Kahl BS, Hong F, Williams M, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts). 118(21):LBA-6
17. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year followup. J Clin Oncol. 2004;22(23):4711-6
18. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-32
19. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-23
20. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-86
21. M. Federico M, Luminari S, Dondi A, et al. R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage follicular lymphoma. Preliminary results of FOLL05 IIL trial. Ann Oncol 2011;22(Suppl. 4): Abstract 135
22. Nastoupil L, Sinha R, Byrtek M, et al. A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. Blood (ASH Annual Meeting Abstracts). 2011;118: Abstract 97
23. Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006;24(22):3604-10
24. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Feb 19. Epub ahead of print.
25. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 2003;21(1):5-15
26. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416-23
27. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29):4480-4
28. Taverna CJ, Bassi S, Hitz F, et al. Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 1802
29. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51
30. Поддубная И.В. Рецидивы фолликулярной лимфомы: проблемы и пути решения. Современная онкология. 2011;1:10-15
31. Rigacci L, Puccini B, Cortelazzo S, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol. 2012;91(7):1013-22
32. Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29(25):3389-95
33. Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximabsensitive follicular lymphoma: a randomized phase 3 trial. Lancet Oncol. 2011;12(8):773-784
34. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927
35. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614-3620.

Для продолжения работы требуется Registration

Предыдущая страница

Следующая страница

СПИСОК СОКРАЩЕНИЙ

Методология написания рекомендаций

Диагностика +

Лечение +

Приложение. Схемы терапии.

ЛИТЕРАТУРА

Данный блок поддерживает скрол*

ЛИТЕРАТУРА

Table of contents